Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 13/20 | 0.73 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373 | 1.00 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2251 | 1.00 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL29669823 | 1.00 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2353 | 0.94 | AGTR1 (0.65) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL683543 | 0.94 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL4473044 | 0.93 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2758 | 0.93 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8476198 | 0.93 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL24998852 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL21125607 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102649780-A | Improved process for synthesizing valsartan | GUANGDONG HEC PHARMACEUTICAL | 2012-08-29 | — | — | CN | claimed |
| CN-102321038-A | Improved valsartan preparation method | ANHUI PROVINCE HONG SHENG BIO TECHNOLOGY CO LTD | 2012-01-18 | — | — | CN | claimed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | claimed |
| WO-2023148748-A1 | AN IMPROVED SAFE PROCESS FOR THE PREPARATION OF SARTAN DRUGS OF FORMULA I | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | ALKEM LABORATORIES LTD. (IN) | 2014-10-23 | — | — | US | disclosed |
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | ALKEM LABORATORIES LTD. (IN) | 2014-10-23 | — | — | US | disclosed |
| CN-102321038-B | Improved valsartan preparation method | ANHUI PROVINCE HONG SHENG BIO TECHNOLOGY CO LTD | 2014-03-26 | — | — | CN | disclosed |
| US-20130137737-A1 | HIGHLY CRYSTALLINE VALSARTAN | NOVARTIS AG (CH) | 2013-05-30 | — | — | US | disclosed |
| WO-2013072924-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF. | ALKEM LABORATORIES LTD. (IN) | 2013-05-23 | — | — | WO | disclosed |
| CN-102649780-A | Improved process for synthesizing valsartan | GUANGDONG HEC PHARMACEUTICAL | 2012-08-29 | — | — | CN | disclosed |
| CN-102584733-A | Improved method for preparing valsartan | ANHUI MODERN NATURAL BIOLOG CO LTD | 2012-07-18 | — | — | CN | disclosed |
| CN-102321038-A | Improved valsartan preparation method | ANHUI PROVINCE HONG SHENG BIO TECHNOLOGY CO LTD | 2012-01-18 | — | — | CN | disclosed |
| US-7880015-B2 | treating N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester with oxalic acid to produce N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester oxalate, treating intermediate with a base and vlaeryl chloride , deprotecting; Valsartan product | AUROBINDO PHARMA LTD. (IN) | 2011-02-01 | — | — | US | disclosed |
| US-7880015-B2 | treating N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester with oxalic acid to produce N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester oxalate, treating intermediate with a base and vlaeryl chloride , deprotecting; Valsartan product | AUROBINDO PHARMA LTD. (IN) | 2011-02-01 | — | — | US | disclosed |
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | AUROBINDO PHARMA LTD (IN) | 2009-11-12 | — | — | US | disclosed |
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | AUROBINDO PHARMA LTD (IN) | 2009-11-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | REN, VCL, PTMS | AGTR1 7/4885LTB4R2 1367/4885ABCB11 493/4885 |
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | AGTR1, AGTR2, AVPR2 | AGTR1 1/4885LTB4R2 747/4885ABCB11 3420/4885 |
| US-20130137737-A1 | HIGHLY CRYSTALLINE VALSARTAN | ACE, REN, ACE2 | AGTR1 8/4885LTB4R2 2018/4885ABCB11 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.